Dr. Robert I. Liem VIII, MD
Pediatric Hematology & Oncology (Pediatric Hematology & Oncology Physician)
225 E Chicago Ave
Chicago, IL 60611
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
At a glance
- Medical school
- Northwestern University Feinberg Medical School (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2006
Licensed in Illinois since 1999, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: Northwestern University Feinberg Medical School
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Hematology & Oncology Physician primary
IL license 036101610 (first issued 1999; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
Medical groups
- Lurie Children's Medical Group Inc. (151 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $230,311 in research payments for these studies, mostly to the institutions running them.
- A Long-term Follow-up Study of Subjects with B-Thalassemia or Sickle Cell Disease Treated with Autologous CRISPR-Cas9 modified Hematopoietic Stem Cells
Vertex Pharmaceuticals Incorporated - Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy
Genetix Biotherapeutics Inc · Active, not recruiting · NCT02633943 - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease
Vertex Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.